1 868 kr
Kommande
1 868 kr
Kommande
567 kr
Skickas inom 10-15 vardagar
739 kr
Läs direkt efter köp
As the Baby Boomers age, concerns over healthcare systems abilities to accommodate geriatric patients grow increasingly challenging. The increased life expectancy of the population since the early 1900s had been built on the improvement of living conditions, diet, public health and advancement in medical care. With this we have seen a steady decline in the age-specific prevalence of vascular and heart diseases, stroke and even dementia.
In addition, societies worldwide struggle to develop a large enough workforce to treat aging patients, which forces geriatric patients to rely on physicians in a wide array of specialties that are often not trained for their demographic. These trends have created a tremendous need for trustworthy resources, yet with regard to hypotensive syndromes, nothing of this nature exists.
Hypotensive syndromes represent a heterogenous group of disease states. Hypotensive syndromes are characterized by low blood pressure following postural changes,meals and neck turning. These are common conditions seen in the elderly and could be due to blood pressure dysregulation. These syndromes frequently cause dizziness, syncope and falls in the elderly as well as a resultant decrease in function, and they are frequently mistaken for other conditions. This is especially true among physicians who are not trained to consider the unique needs of an aging patient.
The proposed book is designed to present a comprehensive approach to the management of hypotensive syndromes in the elderly. Currently there are no guidelines or good resource to guide about these conditions. This book will also discuss the challenges of diagnosis and management of these conditions. The text introduces the concepts to set a clear foundation before covering the syndromes as they present in other comorbidities, including diabetes, heart failure, and a wide array of serious conditions that are common in older patients. As the Baby Boomers continue to age, this text will prove a vital resource for a wide array of specialties that will be increasingly critical to meeting their needs.
2 471 kr
Skickas inom 10-15 vardagar
2 291 kr
Läs direkt efter köp
1 743 kr
Skickas inom 10-15 vardagar
2 237 kr
Skickas inom 7-10 vardagar
2 992 kr
Läs direkt efter köp
1 123 kr
Skickas inom 10-15 vardagar
1 292 kr
Läs direkt efter köp
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.
Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.
Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
1 011 kr
Skickas inom 10-15 vardagar